{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:22:08Z","timestamp":1792794128931,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pregnant women must take medications to treat or prevent specific health conditions that arise during the gestational period. Glibenclamide (GBC), metformin (MET), or insulin (INS) can be prescribed to treat gestational diabetes; Folic acid (FA) is also prescribed during pregnancy to prevent newborn malformations. GBC and FA have low solubility and, therefore, low bioavailability. Amino acids (AA) have been previously proven to be efficient co-formers in binary systems, enhancing drug solubility in water. In this study, highly soluble pharmaceutical ternary formulations of GBC were prepared with FA and the amino acid arginine (ARG). Although ARG has been previously reported as a co-former in GBC binary co-amorphous formulations, it has not been studied in molar ratios higher than 1:2. The results show that ARG may play a role as a co-former and wettability agent depending on its concentration. Ball milling was chosen to prepare the amorphous systems, testing different molar ratios (GBC:ARG: FA at 1:1:0.4, 1:2:0.4, and 1:10:0.4). The presence of glass transition, broad FT-IR bands, and the absence of X-ray diffraction\u00a0peaks confirmed  amorphization of GBC in the milled samples. Solubility results show that ARG may act as a wettability agent when present in the ratio GBC:ARG:FA 1:10:0.4, since even in the physical mixture, an enhancement of GBC solubility of 897-fold was achieved, and as a co-former since the amorphous GBC-ARG-FA formulation showed an increment of 1287-fold. The enhanced solubility of GBC in these ternary systems makes them potential formulations for simultaneously addressing health conditions through combination therapy with FA.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03256-8","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:20:38Z","timestamp":1762888838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Highly Soluble Ternary Amorphous Glibenclamide-Arginine-Folic Acid Formulation Using Arginine as a Coformer, and Wettability Agent"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4531-8071","authenticated-orcid":false,"given":"Karen","family":"P\u00e9rez-Carre\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-1621","authenticated-orcid":false,"given":"Luz Mar\u00eda","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-2127","authenticated-orcid":false,"given":"Marcelo","family":"Videa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-535X","authenticated-orcid":false,"given":"Jorge","family":"Cruz-Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3759-4532","authenticated-orcid":false,"given":"Alejandra","family":"Flores-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"3256_CR1","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.3390\/jcm11195736","volume":"11","author":"R Modzelewski","year":"2022","unstructured":"Modzelewski R, Stefanowicz-Rutkowska MM, Matuszewski W, Bandurska-Stankiewicz EM. Gestational diabetes mellitus\u2014recent literature review. J Clin Med. 2022;11:5736.","journal-title":"J Clin Med"},{"key":"3256_CR2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025."},{"key":"3256_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12902-024-01727-w","volume":"24","author":"K Nabrdalik","year":"2024","unstructured":"Nabrdalik K, Hendel M, Irlik K, Kwiendacz H, \u0141oniewski I, Bucci T, et al. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies. BMC Endocr Disord. 2024;24:206.","journal-title":"BMC Endocr Disord"},{"key":"3256_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1347047","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Ren L, Jia X, Wang J, Cong B. Understanding the action mechanisms of metformin in the gastrointestinal tract. Front Pharmacol. 2024;15: 1347047.","journal-title":"Front Pharmacol"},{"key":"3256_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5005\/jp-journals-10006-1167","volume":"4","author":"P Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide: can it be a substitute to insulin in the management of gestational diabetes mellitus? A comparative study. J South Asian Fed Obstet Gynaecol. 2012;4:28\u201331.","journal-title":"J South Asian Fed Obstet Gynaecol"},{"key":"3256_CR6","first-page":"398","volume":"25","author":"D Ravid","year":"2023","unstructured":"Ravid D, Kovo M, Leytes S, Yagur Y, Fakterman M, Weitzner O. Insulin detemir versus glibenclamide in gestational diabetes mellitus: a retrospective cohort study. Isr Med Assoc J. 2023;25:398\u2013401.","journal-title":"Isr Med Assoc J"},{"key":"3256_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/2008-7802.184502","volume":"7","author":"M Behrashi","year":"2016","unstructured":"Behrashi M, Samimi M, Ghasemi T, Saberi F, Atoof F. Comparison of glibenclamide and insulin on neonatal outcomes in pregnant women with gestational diabetes. Int J Prev Med. 2016;7:88.","journal-title":"Int J Prev Med"},{"key":"3256_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/1947-2714.150081","volume":"7","author":"S Kalra","year":"2015","unstructured":"Kalra S, Gupta Y, Kalra B, Singla R. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. North Am J Med Sci. 2015;7:6.","journal-title":"North Am J Med Sci"},{"key":"3256_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/AOG.0b013e3181c52132","volume":"115","author":"LE Moore","year":"2010","unstructured":"Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with Glyburide in gestational diabetes. Obstet Gynecol. 2010;115:55\u20139.","journal-title":"Obstet Gynecol"},{"key":"3256_CR10","doi-asserted-by":"publisher","first-page":"116185","DOI":"10.1016\/j.ejmech.2024.116185","volume":"267","author":"Y-Y Guo","year":"2024","unstructured":"Guo Y-Y, Zhang J-Y, Sun J-F, Gao H. A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: synthetic approaches and clinical applications. Eur J Med Chem. 2024;267:116185.","journal-title":"Eur J Med Chem"},{"key":"3256_CR11","doi-asserted-by":"crossref","unstructured":"Faraji A, Tahamtani L, Maharlouei N, Asadi N. Effects of oral glibenclamide versus subcutaneous insulin on perinatal outcome of patients with gestational diabetes mellitus: A randomized clinical trial. 16:98\u2013103.","DOI":"10.1177\/1753495X221100167"},{"key":"3256_CR12","unstructured":"National Library of Medicine-National Center for Biotechnology Information. PubChem Compound Summary for CID 3488, Glyburide. [Internet]. 2021. Available from:  https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Magnesium-citrate"},{"key":"3256_CR13","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.3390\/nu5114760","volume":"5","author":"AE Czeizel","year":"2013","unstructured":"Czeizel AE, Dud\u00e1s I, Vereczkey A, B\u00e1nhidy F. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013;5:4760\u201375.","journal-title":"Nutrients"},{"key":"3256_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020272","volume":"11","author":"L Kaldygulova","year":"2023","unstructured":"Kaldygulova L, Ukybassova T, Aimagambetova G, Gaiday A, Tussupkaliyev A. Biological role of folic acid in pregnancy and possible therapeutic application for the prevention of preeclampsia. Biomedicines. 2023;11: 272.","journal-title":"Biomedicines"},{"key":"3256_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/nu17010126","volume":"17","author":"V R\u00edsov\u00e1","year":"2024","unstructured":"R\u00edsov\u00e1 V, Saade R, Jaku\u0161 V, Gajdo\u0161ov\u00e1 L, Varga I, Z\u00e1humensk\u00fd J. Preconceptional and periconceptional folic acid supplementation in the Visegrad Group countries for the prevention of neural tube defects. Nutrients. 2024;17: 126.","journal-title":"Nutrients"},{"key":"3256_CR16","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1080\/10408398.2021.1989658","volume":"63","author":"Y Cui","year":"2023","unstructured":"Cui Y, Liao M, Xu A, Chen G, Liu J, Yu X, et al. Association of maternal pre-pregnancy dietary intake with adverse maternal and neonatal outcomes: a systematic review and meta-analysis of prospective studies. Crit Rev Food Sci Nutr. 2023;63:3430\u201351.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"3256_CR17","doi-asserted-by":"publisher","first-page":"112383","DOI":"10.1016\/j.nut.2024.112383","volume":"122","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu Z, Sun K, Zhao J, Huang H, Zhang C. Association of serum folic acid levels in response to fasting blood glucose in early pregnancy with the risk of gestational diabetes mellitus: a retrospective cohort study. Nutrition. 2024;122:112383.","journal-title":"Nutrition"},{"key":"3256_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/nu15122766","volume":"15","author":"R Xu","year":"2023","unstructured":"Xu R, Liu S, Zhong Z, Guo Y, Xia T, Chen Y, et al. The influence of maternal folate status on gestational diabetes mellitus: a systematic review and meta-analysis. Nutrients. 2023;15: 2766.","journal-title":"Nutrients"},{"key":"3256_CR19","first-page":"98","volume":"36","author":"M Dey","year":"2023","unstructured":"Dey M, Dhume P, Sharma SK, Goel S, Chawla S, Shah A, et al. Folic acid: The key to a healthy pregnancy \u2013 A prospective study on fetomaternal outcome. Tzu Chi Med J. 2023;36:98\u2013102.","journal-title":"Tzu Chi Med J."},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00381-023-05910-7","volume":"39","author":"V Kancherla","year":"2023","unstructured":"Kancherla V. Neural tube defects: a review of global prevalence, causes, and primary prevention. Childs Nerv Syst. 2023;39:1703\u201310.","journal-title":"Childs Nerv Syst"},{"key":"3256_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","volume":"58","author":"M Lindenberg","year":"2004","unstructured":"Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"3256_CR22","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.jddst.2019.101242","volume":"54","author":"AD Le\u00e3o","year":"2019","unstructured":"Le\u00e3o AD, Profiro JHO, Nunes LCC, Silva-Filho EC, Soares MFR, Soares-Sobrinho JL. Strategies to improve glibenclamide dissolution: a review using database tomography. J Drug Deliv Sci Technol. 2019;54:101242.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3256_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/10837450.2014.920352","volume":"20","author":"KR Bellavinha","year":"2015","unstructured":"Bellavinha KR, Silva-Barcellos NM, Souza JB, Leite JC, Souza JD. Folic acid: a biopharmaceutical evaluation. Pharm Dev Technol. 2015;20:730\u20137.","journal-title":"Pharm Dev Technol"},{"key":"3256_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/life13051099","volume":"13","author":"L Kumari","year":"2023","unstructured":"Kumari L, Choudhari Y, Patel P, Gupta GD, Singh D, Rosenholm JM, et al. Advancement in solubilization approaches: a step towards bioavailability enhancement of poorly soluble drugs. Life. 2023;13: 1099.","journal-title":"Life"},{"key":"3256_CR25","doi-asserted-by":"publisher","first-page":"103883","DOI":"10.1016\/j.drudis.2024.103883","volume":"29","author":"H Wang","year":"2024","unstructured":"Wang H, Zhao P, Ma R, Jia J, Fu Q. Drug\u2013drug co-amorphous systems: an emerging formulation strategy for poorly water-soluble drugs. Drug Discov Today. 2024;29:103883.","journal-title":"Drug Discov Today"},{"key":"3256_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102003","volume":"14","author":"LM Mart\u00ednez","year":"2022","unstructured":"Mart\u00ednez LM, Cruz-Angeles J, V\u00e1zquez-D\u00e1vila M, Mart\u00ednez E, Cabada P, Navarrete-Bernal C, et al. Mechanical activation by ball milling as a strategy to prepare highly soluble pharmaceutical formulations in the form of co-amorphous, co-crystals, or polymorphs. Pharmaceutics. 2022;14: 2003.","journal-title":"Pharmaceutics"},{"key":"3256_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1208\/s12249-019-1359-2","volume":"20","author":"J Cruz-Angeles","year":"2019","unstructured":"Cruz-Angeles J, Videa M, Mart\u00ednez LM. Highly soluble Glimepiride and Irbesartan co-amorphous formulation with potential application in combination therapy. AAPS PharmSciTech. 2019;20:144.","journal-title":"AAPS PharmSciTech"},{"key":"3256_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules23092161","volume":"23","author":"C Mart\u00ednez-Jim\u00e9nez","year":"2018","unstructured":"Mart\u00ednez-Jim\u00e9nez C, Cruz-Angeles J, Videa M, Mart\u00ednez LM. Co-amorphous simvastatin-nifedipine with enhanced solubility for possible use in combination therapy of hypertension and hypercholesterolemia. Molecules. 2018;23:1\u201313.","journal-title":"Molecules"},{"key":"3256_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1208\/s12249-025-03045-3","volume":"26","author":"J Cruz-Angeles","year":"2025","unstructured":"Cruz-Angeles J, Mart\u00ednez LM, L\u00f3pez L\u00f3pez AM, Cabada-Aguirre P, Videa M, Flores A. Long-term stabilized and highly soluble Bezafibrate-Gliclazide co-amorphous binary system. AAPS PharmSciTech. 2025;26:48.","journal-title":"AAPS PharmSciTech"},{"key":"3256_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/acs.molpharmaceut.2c00873","volume":"20","author":"NA Vasilev","year":"2023","unstructured":"Vasilev NA, Voronin AP, Surov AO, Perlovich GL. Influence of co-amorphization on the physical stability and dissolution performance of an anthelmintic drug Flubendazole. Mol Pharm. 2023;20:1657\u201369.","journal-title":"Mol Pharm"},{"key":"3256_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1208\/s12249-024-02799-6","volume":"25","author":"J Haneef","year":"2024","unstructured":"Haneef J, Ali S. Multicomponent amorphous solid forms of Telmisartan: insights into mechanochemical activation and physicochemical attributes. AAPS PharmSciTech. 2024;25:84.","journal-title":"AAPS PharmSciTech"},{"key":"3256_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1248\/cpb.c23-00673","volume":"72","author":"S Oyama","year":"2024","unstructured":"Oyama S, Ogawa N, Kawai K, Iwai K, Yasunaga T, Yamamoto H. Improved dissolution properties of co-amorphous Probucol with Atorvastatin calcium trihydrate prepared by spray-drying. Chem Pharm Bull (Tokyo). 2024;72:190\u20139.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"3256_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","volume":"95","author":"G Kasten","year":"2016","unstructured":"Kasten G, Grohganz H, Rades T, L\u00f6bmann K. Development of a screening method for co-amorphous formulations of drugs and amino acids. Eur J Pharm Sci. 2016;95:28\u201335.","journal-title":"Eur J Pharm Sci"},{"key":"3256_CR34","doi-asserted-by":"crossref","unstructured":"Chabukswar AR, Jagdale SC, Gandhi PM. Amino acid conjugation: An approach to enhance aqueous solubility and permeability of poorly water soluble drug ritonavir. J Drug Delivery Ther. 2019;9(3):252\u2013256.","DOI":"10.22270\/jddt.v9i3.2848"},{"key":"3256_CR35","doi-asserted-by":"publisher","first-page":"121375","DOI":"10.1016\/j.ijpharm.2021.121375","volume":"613","author":"A Bongioanni","year":"2022","unstructured":"Bongioanni A, Bueno MS, Mezzano BA, Longhi MR, Garnero C. Amino acids and its pharmaceutical applications: a mini review. Int J Pharm. 2022;613:121375.","journal-title":"Int J Pharm"},{"key":"3256_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112544","volume":"15","author":"K P\u00e9rez-Carre\u00f3n","year":"2023","unstructured":"P\u00e9rez-Carre\u00f3n K, Mart\u00ednez LM, Videa M, Cruz-Angeles J, G\u00f3mez J, Ram\u00edrez E. Effect of basic amino acids on folic acid solubility. Pharmaceutics. 2023;15: 2544.","journal-title":"Pharmaceutics"},{"key":"3256_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.70632\/jbbr.8.2.2024.52-60","volume":"8","author":"E S\u00e1nchez","year":"2024","unstructured":"S\u00e1nchez E, Garc\u00eda-Alvarado A, Cruz-Angeles J, P\u00e9rez-Carre\u00f3n K, Videa M, Mart\u00ednez LM. Using amino acids to enhance the solubility of Glibenclamide in pharmaceutical formulations for the treatment and prevention of gestational diabetes. Journal of Bioengineering and Biomedicine Research. 2024;8:52\u201360.","journal-title":"Journal of Bioengineering and Biomedicine Research"},{"key":"3256_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejpb.2018.06.007","volume":"129","author":"M Ruponen","year":"2018","unstructured":"Ruponen M, Visti M, Ojarinta R, Laitinen R. Permeability of glibenclamide through a PAMPA membrane: the effect of co-amorphization. Eur J Pharm Biopharm. 2018;129:247\u201356.","journal-title":"Eur J Pharm Biopharm"},{"key":"3256_CR39","doi-asserted-by":"publisher","first-page":"102126","DOI":"10.1016\/j.mtcomm.2021.102126","volume":"26","author":"VB Sterren","year":"2021","unstructured":"Sterren VB, Zoppi A, Abraham-Miranda J, Longhi MR. Enhanced dissolution profiles of glibenclamide with amino acids using a cogrinding method. Mater Today Commun. 2021;26:102126.","journal-title":"Mater Today Commun"},{"key":"3256_CR40","doi-asserted-by":"publisher","first-page":"118653","DOI":"10.1016\/j.ijpharm.2019.118653","volume":"570","author":"H Sormunen","year":"2019","unstructured":"Sormunen H, Ruponen M, Laitinen R. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm. 2019;570:118653.","journal-title":"Int J Pharm"},{"key":"3256_CR41","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4314\/tjpr.v21i7.1","volume":"21","author":"SO Arag\u00f3n-Aburto","year":"2022","unstructured":"Arag\u00f3n-Aburto SO, Mondrag\u00f3n-V\u00e1squez K, Valerio- Alfaro G, Dom\u00ednguez-Ch\u00e1vez JG. Characterization, stability and solubility of co-amorphous systems of glibenclamide and L-arginine at different pH. Trop J Pharm Res. 2022;21:1355\u201364.","journal-title":"Trop J Pharm Res"},{"key":"3256_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.molliq.2017.05.068","volume":"240","author":"MMRMM Affandi","year":"2017","unstructured":"Affandi MMRMM, Tripathy M, Majeed ABA. Solubility enhancement of simvastatin and atorvastatin by arginine: contact angle determination, wettability and surface energy characteristics. J Mol Liq. 2017;240:340\u20134.","journal-title":"J Mol Liq"},{"key":"3256_CR43","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s11095-023-03491-3","volume":"40","author":"A Newman","year":"2023","unstructured":"Newman A, Zografi G. Perspectives on the wetting of solids in pharmaceutical systems. Pharm Res. 2023;40:3099\u2013118.","journal-title":"Pharm Res"},{"key":"3256_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/powders3020015","volume":"3","author":"J Brubaker","year":"2024","unstructured":"Brubaker J, Moghtadernejad S. A comprehensive review of the rheological properties of powders in pharmaceuticals. Powders. 2024;3:233\u201354.","journal-title":"Powders"},{"key":"3256_CR45","doi-asserted-by":"publisher","first-page":"103843","DOI":"10.1016\/j.jddst.2022.103843","volume":"77","author":"J Kukkonen","year":"2022","unstructured":"Kukkonen J, Ervasti T, Laitinen R. Production and characterization of glibenclamide incorporated PLA filaments for 3D printing by fused deposition modeling. J Drug Deliv Sci Technol. 2022;77:103843.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3256_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.colsurfa.2010.04.040","volume":"364","author":"AF Stalder","year":"2010","unstructured":"Stalder AF, Melchior T, M\u00fcller M, Sage D, Blu T, Unser M. Low-bond axisymmetric drop shape analysis for surface tension and contact angle measurements of sessile drops. Colloids Surf A Physicochem Eng Asp. 2010;364:72\u201381.","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"3256_CR47","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1021\/mp500107s","volume":"11","author":"R Laitinen","year":"2014","unstructured":"Laitinen R, L\u00f6bmann K, Grohganz H, Strachan C, Rades T. Amino acids as co-amorphous excipients for Simvastatin and Glibenclamide: physical properties and stability. Mol Pharm. 2014;11:2381\u20139.","journal-title":"Mol Pharm"},{"key":"3256_CR48","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1021\/mp100077c","volume":"7","author":"Z Wojnarowska","year":"2010","unstructured":"Wojnarowska Z, Grzybowska K, Adrjanowicz K, Kaminski K, Paluch M, Hawelek L, et al. Study of the amorphous glibenclamide drug: analysis of the molecular dynamics of quenched and cryomilled material. Mol Pharm. 2010;7:1692\u2013707.","journal-title":"Mol Pharm"},{"key":"3256_CR49","doi-asserted-by":"crossref","unstructured":"Barghi L, Vekalati A, Jahangiri A. Stability-Enhanced Ternary Solid Dispersions of Glyburide: Effect of Preparation Method on Physicochemical Properties. Suksaeree J, editor. Adv Pharmacol Pharm Sci. 2023;2023:1\u20139.","DOI":"10.1155\/2023\/2641153"},{"key":"3256_CR50","unstructured":"Akhgari A, Iraji P, Rahiman N, Hasanzade Farouji A, Abbaspour M. Preparation of stable enteric folic acid-loaded microfiber using the electrospinning method. Iran J Basic Med Sci. 2022;25."},{"key":"3256_CR51","doi-asserted-by":"publisher","first-page":"120981","DOI":"10.1016\/j.saa.2022.120981","volume":"273","author":"VR Magri","year":"2022","unstructured":"Magri VR, Rocha MA, De Matos CS, Petersen PAD, Leroux F, Petrilli HM, et al. Folic acid and sodium folate salts: thermal behavior and spectroscopic (IR, raman, and solid-state 13C NMR) characterization. Spectrochim Acta A Mol Biomol Spectrosc. 2022;273:120981.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03256-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:02:43Z","timestamp":1770318163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03256-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03256-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"29"}}